Content area
Full text
The FDA recently approved Flucelvax Quadrivalent - the first seasonal influenza vaccine to be cell-derived and to protect against the four major strains of influenza A and B - for patients aged 4 years and older, according to its manufacturer.
"Flucelvax Quadrivalent will provide health care providers and their patients with an important option to further broaden their influenza coverage," Gordon Naylor, MBA, president of Seqirus, said in a press release.
Traditional trivalent influenza vaccines protect against two strains of influenza A virus...